- Home
- CLSD vs CRVO Comparison
CLSD vs CRVO Comparison
Compare CLSD & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- CRVO
- Stock Information
- Founded
- CLSD 2011
- CRVO 2001
- Country
- CLSD United States
- CRVO United States
- Employees
- CLSD N/A
- CRVO N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- CLSD Health Care
- CRVO Health Care
- Exchange
- CLSD Nasdaq
- CRVO Nasdaq
- Market Cap
- CLSD 68.4M
- CRVO 67.4M
- IPO Year
- CLSD 2016
- CRVO N/A
- Fundamental
- Price
- CLSD $0.35
- CRVO $9.99
- Analyst Decision
- CLSD Hold
- CRVO Strong Buy
- Analyst Count
- CLSD 4
- CRVO 6
- Target Price
- CLSD $4.33
- CRVO $19.17
- AVG Volume (30 Days)
- CLSD 582.0K
- CRVO 113.2K
- Earning Date
- CLSD 08-08-2025
- CRVO 08-08-2025
- Dividend Yield
- CLSD N/A
- CRVO N/A
- EPS Growth
- CLSD N/A
- CRVO N/A
- EPS
- CLSD N/A
- CRVO N/A
- Revenue
- CLSD $4,166,000.00
- CRVO $7,776,968.00
- Revenue This Year
- CLSD $98.20
- CRVO N/A
- Revenue Next Year
- CLSD $213.77
- CRVO N/A
- P/E Ratio
- CLSD N/A
- CRVO N/A
- Revenue Growth
- CLSD N/A
- CRVO N/A
- 52 Week Low
- CLSD $0.29
- CRVO $1.80
- 52 Week High
- CLSD $1.65
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- CLSD 33.25
- CRVO 55.93
- Support Level
- CLSD $0.39
- CRVO $9.61
- Resistance Level
- CLSD $0.36
- CRVO $10.89
- Average True Range (ATR)
- CLSD 0.03
- CRVO 0.62
- MACD
- CLSD 0.00
- CRVO 0.02
- Stochastic Oscillator
- CLSD 14.77
- CRVO 57.75
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.